Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

ADPT

Adaptive Biotechnologies Corp

Feb 06 • 04:00PM ET

15.77

-0.70 -4.25 %

Healthcare • Biotechnology • USA • NASD

Peers: ILMN TXG GH PACB QGEN TWST FATE BEAM CRSP VRTX

| Held by: VTI IWM ARKG VB IWO VXF IBB VBK VTWO SCHA

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-0.40	Insider Own	3.77%	Shs Outstand	153.78M	Perf Week	-14.76%
Market Cap	2.41B	Forward P/E	-	EPS next Y	-0.30	Insider Trans	-21.88%	Shs Float	146.91M	Perf Month	-5.74%
Enterprise Value	2.40B	PEG	-	EPS next Q	-0.16	Inst Own	94.03%	Short Float	6.14%	Perf Quarter	-10.35%
Income	-59.50M	P/S	8.69	EPS this Y	-33.46%	Inst Trans	-1.60%	Short Ratio	3.74	Perf Half Y	25.76%
Sales	276.98M	P/B	11.08	EPS next Y	42.36%	ROA	-11.31%	Short Interest	9.02M	Perf YTD	-2.89%
Book/sh	1.42	P/C	10.61	EPS next 5Y	30.08%	ROE	-28.23%	52W High	20.76 -24.04%	Perf Year	95.90%
Cash/sh	1.49	P/FCF	-	EPS past 3/5Y	34.64% 18.85%	ROIC	-14.32%	52W Low	6.26 152.12%	Perf 3Y	68.12%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	14.34% 23.00%	Gross Margin	70.70%	Volatility	10.44% 6.64%	Perf 5Y	-71.93%
Dividend TTM	-	EV/Sales	8.65	EPS Y/Y TTM	63.63%	Oper. Margin	-20.62%	ATR (14)	1.21	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	3.23	Sales Y/Y TTM	54.77%	Profit Margin	-21.48%	RSI (14)	36.69	Recom	1.25
Dividend Gr. 3/5Y	- -	Current Ratio	3.34	EPS Q/Q	61.13%	SMA20	-12.05%	Beta	2.19	Target Price	20.86
Payout	-	Debt/Eq	0.96	Sales Q/Q	51.04%	SMA50	-8.38%	Rel Volume	1.72	Prev Close	16.47
Employees	619	LT Debt/Eq	0.90	Earnings	Feb 05 AMC	SMA200	16.25%	Avg Volume	2.41M	Price	15.77
IPO	Jun 27, 2019	Option/Short	Yes / Yes	EPS/Sales Surpr.	51.48% 17.72%	Trades		Volume	4,139,276	Change	-4.25%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-02-25	Resumed	Morgan Stanley	Equal-Weight	$21
Sep-30-25	Initiated	Guggenheim	Buy	$20
Jun-18-25	Initiated	Craig Hallum	Buy	$15
Mar-21-25	Upgrade	Goldman	Neutral → Buy	$9
Jul-05-23	Resumed	JP Morgan	Overweight	$15
Jan-05-23	Initiated	Scotiabank	Sector Outperform	$15
Dec-21-22	Upgrade	Piper Sandler	Neutral → Overweight	$7.50 → $14
Aug-25-22	Initiated	Credit Suisse	Underperform	$8
Jun-03-22	Initiated	Piper Sandler	Neutral	$7.50
Feb-16-22	Reiterated	JP Morgan	Overweight	$75 → $50
Feb-16-22	Reiterated	Goldman	Neutral	$54 → $21
Feb-16-22	Reiterated	BTIG Research	Buy	$35 → $30
Feb-16-22	Reiterated	BofA Securities	Buy	$40 → $32
Oct-15-21	Resumed	Cowen	Outperform
Mar-03-21	Downgrade	Goldman	Buy → Neutral	$74 → $63
Oct-08-20	Resumed	BTIG Research	Buy	$60
Sep-09-20	Initiated	Morgan Stanley	Equal-Weight	$42
Jun-03-20	Initiated	Goldman	Buy	$60
Jul-23-19	Initiated	BTIG Research	Buy	$46
Jul-22-19	Initiated	William Blair	Outperform

Show Previous Ratings

Feb-06-26 12:05AM	Adaptive Biotechnologies Corp (ADPT) Q4 2025 Earnings Call Highlights: Strong Revenue Growth ... (GuruFocus.com)
Feb-05-26 08:06PM	Adaptive Biotechnologies Q4 Earnings Call Highlights (MarketBeat)
07:30PM	Adaptive Biotechnologies (ADPT) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
05:35PM	Adaptive Biotechnologies (ADPT) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
04:53PM	Adaptive Biotechnologies: Q4 Earnings Snapshot (Associated Press Finance)
04:05PM	Loading…
04:05PM	Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2025 Financial Results (GlobeNewswire)
Jan-27-26 04:05PM	Adaptive Biotechnologies to Participate in Upcoming Investor Conferences (GlobeNewswire)
Jan-22-26 04:05PM	Adaptive Biotechnologies to Report Fourth Quarter and Full Year 2025 Financial Results on February 5, 2026 (GlobeNewswire) +8.48%
Jan-13-26 09:40AM	What's Going On With Adaptive Biotechnologies Shares Tuesday? (Benzinga)
Jan-12-26 09:06PM	Adaptive Biotechnologies Touts clonoSEQ MRD Growth, Targets Companywide Profitability in 2026 (MarketBeat) +15.86%
07:30AM	Adaptive Biotechnologies Announces Preliminary Fourth Quarter and Full Year 2025 Results (GlobeNewswire)
Dec-30-25 04:05PM	Adaptive Biotechnologies to Present at the 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-15-25 08:00AM	Adaptive Biotechnologies Announces Two Immune Receptor Licensing Agreements with Pfizer (GlobeNewswire)
Dec-09-25 05:07PM	Adaptive Biotechnologies to Participate in Jefferies Fireside Chat Series on Minimal Residual Disease (GlobeNewswire) +5.92%
Dec-08-25 02:16AM	Adaptive Biotechnologies (ADPT) Falls 24.5% as Execs Dispose Millions of Stake (Insider Monkey)
08:30AM	Loading…
Dec-06-25 08:30AM	Adaptive Biotechnologies Showcases Leadership in Hematology-Oncology MRD with New clonoSEQ Data Driving Treatment Interventions at 2025 ASH Annual Meeting (GlobeNewswire)
Nov-24-25 07:30AM	Adaptive Biotechnologies Announces Nearly 90 Abstracts Featuring clonoSEQ MRD Testing Across a Range of Blood Cancers to be Presented at the 67th ASH Annual Meeting (GlobeNewswire) +9.94%
Nov-22-25 10:10AM	Adaptive Biotechnologies (ADPT) Hits 3-Year High. Here's Why (Insider Monkey)
Nov-17-25 09:05AM	Continued Momentum Lifted Adaptive Biotechnologies Corporation (ADPT) in Q3 (Insider Monkey)
Nov-06-25 04:05PM	Adaptive Biotechnologies to Participate in Upcoming Investor Conferences (GlobeNewswire) -11.54%
07:05AM	Cathie Wood Loads Up Pinterest After Sell-Off -- Dumps Shopify, Roku, and Robinhood (GuruFocus.com)
12:03AM	Adaptive Biotechnologies Corp (ADPT) Q3 2025 Earnings Call Highlights: Record Revenue Growth ... (GuruFocus.com)
Nov-05-25 07:30PM	Adaptive Biotechnologies (ADPT) Reports Q3 Earnings: What Key Metrics Have to Say (Zacks)
06:35PM	Adaptive Biotechnologies (ADPT) Reports Q3 Loss, Beats Revenue Estimates (Zacks)
05:31PM	Adaptive Biotechnologies: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Adaptive Biotechnologies Reports Third Quarter 2025 Financial Results (GlobeNewswire)
Nov-04-25 07:45AM	Adaptive Biotechnologies Corp (ADPT) Q3 2025: Everything You Need To Know Ahead Of Earnings (GuruFocus.com)
Oct-30-25 10:00AM	Zymeworks Inc. (ZYME) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release (Zacks)
Oct-29-25 10:00AM	Adaptive Biotechnologies (ADPT) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release (Zacks)
Oct-23-25 10:19AM	IQVIA Gears Up to Report Q3 Earnings: What's in the Cards? (Zacks)
12:10PM	Loading…
Oct-17-25 12:10PM	Can This Red-Hot Biotech Stock Live Up to Wall Streets Expectations? (Barchart) -5.62%
Oct-15-25 04:05PM	Adaptive Biotechnologies to Report Third Quarter 2025 Financial Results on November 5, 2025 (GlobeNewswire) +9.82%
Sep-26-25 10:32AM	LLY Gets EU Approval for Alzheimer's Drug & FDA Nod to Cancer Therapy (Zacks)
09:40AM	Are Medical Stocks Lagging Adaptive Biotechnologies (ADPT) This Year? (Zacks)
Sep-23-25 12:08PM	CRSP & Sirius Begin Dosing in Thromboembolic Disorder Study in EU (Zacks)
Sep-19-25 12:24PM	NTLA Completes Enrollment in Pivotal Study on HAE Candidate, Stock Up (Zacks)
Sep-16-25 12:54PM	Krystal Biotech Stock Up on FDA Nod to Vyjuvek Label Update (Zacks)
Sep-11-25 11:57AM	FDA Accepts Corcept's NDA for Relacorilant in Ovarian Cancer (Zacks) +8.62%
Sep-10-25 11:11AM	IONS Up on FDA's Breakthrough Tag for ION582 in Angelman Syndrome (Zacks)
09:40AM	Is Cardinal Health (CAH) Stock Outpacing Its Medical Peers This Year? (Zacks)
Sep-05-25 11:00AM	AQST Stock Up as FDA Skips Advisory Meeting to Discuss Anaphylm NDA (Zacks)
10:04AM	AGIO Stock Falls as FDA Delays Decision on Pyrukynd for Thalassemia (Zacks)
Sep-04-25 10:48AM	SNY Down Despite Eczema Candidate Meeting Goal in Phase III Study (Zacks)
Sep-01-25 12:30PM	Sanofi Gets FDA Nod for Wayrilz in Immune Thrombocytopenia (Zacks)
12:00PM	Are You Looking for a Top Momentum Pick? Why Adaptive Biotechnologies (ADPT) is a Great Choice (Zacks)
Aug-29-25 09:15AM	Adaptive Biotechnologies Corporation (ADPT) Hits Fresh High: Is There Still Room to Run? (Zacks)
Aug-27-25 04:05PM	Adaptive Biotechnologies to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference (GlobeNewswire)
Aug-25-25 09:40AM	Is Adaptive Biotechnologies (ADPT) Outperforming Other Medical Stocks This Year? (Zacks)
12:08AM	Adaptive Biotechnologies (ADPT) Poised for $33.7M Windfall on Genentech Deal Termination (Insider Monkey)
Aug-19-25 07:13AM	PTC drug for Friedrichs ataxia rejected; Lilly sells nearly $7B in bonds (BioPharma Dive)
Aug-13-25 09:15AM	Adaptive Biotechnologies Corporation (ADPT) Hit a 52 Week High, Can the Run Continue? (Zacks)
Aug-08-25 09:40AM	Has Adaptive Biotechnologies (ADPT) Outpaced Other Medical Stocks This Year? (Zacks)
Aug-06-25 07:01PM	Why Adaptive Biotechnologies Stock Popped by Almost 6% on Wednesday (Motley Fool) +5.79% +7.27%
03:30AM	Adaptive Biotechnologies Corp (ADPT) Q2 2025 Earnings Call Highlights: Strong MRD Growth and ... (GuruFocus.com)
Aug-05-25 07:30PM	Here's What Key Metrics Tell Us About Adaptive Biotechnologies (ADPT) Q2 Earnings (Zacks)
06:00PM	Adaptive Biotechnologies (ADPT) Reports Q2 Loss, Beats Revenue Estimates (Zacks)
04:57PM	Adaptive Biotechnologies: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Adaptive Biotechnologies Reports Second Quarter 2025 Financial Results (GlobeNewswire)
Aug-04-25 09:38AM	Adaptive Biotechnologies Corp (ADPT) Q2 2025: Everything You Need To Know Ahead Of Earnings (GuruFocus.com) +5.61%
Aug-01-25 08:10AM	Moderna (MRNA) Reports Q2 Loss, Beats Revenue Estimates (Zacks)
Jul-22-25 08:14AM	Adaptive Biotechnologies Corporation (ADPT) Rose on Solid Results (Insider Monkey)
Jul-15-25 04:05PM	Adaptive Biotechnologies to Report Second Quarter 2025 Financial Results on August 5, 2025 (GlobeNewswire)
Jul-04-25 09:40AM	Are Medical Stocks Lagging Adaptive Biotechnologies (ADPT) This Year? (Zacks)
Jul-01-25 07:30AM	Adaptive Biotechnologies and Flatiron Health Announce Integration of clonoSEQ MRD Testing into OncoEMR (GlobeNewswire)
Jun-26-25 09:49AM	Adaptive Biotechnologies (ADPT) Surges 12.5%: Is This an Indication of Further Gains? (Zacks)
Jun-25-25 01:01PM	Craig-Hallum Initiates Coverage of Adaptive Biotechnologies (ADPT) stock, Gives Buy (Insider Monkey) +12.49%
Jun-13-25 12:00PM	What Makes Adaptive Biotechnologies (ADPT) a New Buy Stock (Zacks)
Jun-11-25 09:40AM	Is Adaptive Biotechnologies (ADPT) Stock Outpacing Its Medical Peers This Year? (Zacks)
Jun-03-25 04:05PM	Grindr Appoints Veteran Public Company CFO and Audit Committee Chair Chad Cohen to Board of Directors (Business Wire)
May-30-25 07:30AM	Adaptive Biotechnologies Highlights New Data at 2025 ASCO Annual Meeting and EHA 2025 Congress Demonstrating How clonoSEQ MRD Assessment is Optimizing Patient Care and Drug Development in Lymphoid Cancers (GlobeNewswire)
May-29-25 11:18AM	SPRO Stock Soars 245% on GSK-Partnered UTI Drug Meeting Study Goal (Zacks)
11:08AM	U.S. Govt. Cancels $766M Funding Contract for Moderna's Bird Flu Shot (Zacks)
06:20AM	Is First Trust Small Cap Growth AlphaDEX ETF (FYC) a Strong ETF Right Now? (Zacks)
May-28-25 04:05PM	Adaptive Biotechnologies to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference (GlobeNewswire)
May-26-25 09:40AM	Is Adaptive Biotechnologies (ADPT) Outperforming Other Medical Stocks This Year? (Zacks)
May-20-25 06:20AM	Should First Trust Small Cap Growth AlphaDEX ETF (FYC) Be on Your Investing Radar? (Zacks)
May-19-25 09:06AM	BioMarin Offers to Buy Inozyme for $270M to Boost Enzyme Therapy Biz (Zacks)
May-15-25 08:42AM	AbbVie Secures FDA Nod for New ADC Drug Emrelis in Lung Cancer (Zacks)
May-14-25 06:29AM	Allogene's Q1 Earnings In Line With Estimates, Sales Nil (Zacks)
May-09-25 12:41PM	Insmed's Q1 Loss Wider Than Expected, Sales Match Estimates (Zacks)
12:00PM	Adaptive Biotechnologies (ADPT) is a Great Momentum Stock: Should You Buy? (Zacks)
08:55AM	NVAX Stock Gains 12% on Q1 Earnings & Sales Beat, '25 Sales View Up (Zacks)
08:06AM	Iovance's Q1 Earnings & Sales Miss, Stock Slides 39% on '25 View Cut (Zacks)
May-08-25 09:55AM	Does Adaptive Biotechnologies (ADPT) Have the Potential to Rally 26.45% as Wall Street Analysts Expect? (Zacks) +5.22%
09:40AM	Has Adaptive Biotechnologies (ADPT) Outpaced Other Medical Stocks This Year? (Zacks)
May-02-25 09:29AM	Q1 2025 Adaptive Biotechnologies Corp Earnings Call (Thomson Reuters StreetEvents) +33.70%
03:18AM	Adaptive Biotechnologies Corp (ADPT) Q1 2025 Earnings Call Highlights: Strong MRD Revenue ... (GuruFocus.com)
May-01-25 09:46PM	Adaptive Biotechnologies Corporation (ADPT) Q1 2025 Earnings Call Transcript (Seeking Alpha)
07:00PM	Adaptive Biotechnologies (ADPT) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
05:35PM	Adaptive Biotechnologies (ADPT) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:30PM	Adaptive Biotechnologies: Q1 Earnings Snapshot (Associated Press Finance)
04:05PM	Adaptive Biotechnologies Reports First Quarter 2025 Financial Results (GlobeNewswire)
Apr-24-25 09:45AM	Aristotle Focus Growth Q1 2025 Commentary (Seeking Alpha) +6.91%
Apr-14-25 02:09PM	Aristotle Large Cap Growth Q1 2025 Commentary (Seeking Alpha)
Apr-12-25 09:15AM	OpenAI And Andreessen Horowitz Lead $43M Round For Cybersecurity Startup Taking On AI Scammers, Deepfakes, And Voice Spoofs (Benzinga)
Apr-10-25 04:05PM	Adaptive Biotechnologies to Report First Quarter 2025 Financial Results on May 1, 2025 (GlobeNewswire) -7.82%
Apr-08-25 08:00AM	Adaptive Biotechnologies Receives Expanded Medicare Coverage of clonoSEQ for Surveillance in Mantle Cell Lymphoma (GlobeNewswire)
Mar-20-25 03:06PM	Adaptive Biotechnologies (ADPT): Among Stocks Insiders Are Selling In March (InsiderMonkey)
Mar-11-25 08:00AM	Adaptive Biotechnologies Launches Assay Enhancements to Increase clonoSEQ Sensitivity for Clinical MRD Detection in Diffuse Large B-Cell Lymphoma (GlobeNewswire) +12.29%
Feb-14-25 10:44AM	Adaptive Biotechnologies price target raised to $12 from $10 at Scotiabank (TipRanks)

Adaptive Biotechnologies Corp. engages in the development of an immune medicine platform. Its products and services include immunoSEQ, clonoSEQ, cellular therapy, and vaccines. The company was founded by Chad Robins, Harlan Robins, and Chris Carlson on September 8, 2009 and is headquartered in Seattle, WA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
PISKEL KYLE	Chief Financial Officer	Feb 04 '26	Option Exercise	12.14	2,145	26,040	218,782	Feb 06 07:30 PM
PISKEL KYLE	Chief Financial Officer	Feb 04 '26	Sale	18.46	2,145	39,597	216,637	Feb 06 07:30 PM
ROBINS HARLAN S	Chief Scientific Officer	Feb 02 '26	Sale	18.60	34,668	644,825	1,187,644	Feb 04 07:48 PM
ROBINS HARLAN S	Chief Scientific Officer	Feb 03 '26	Sale	19.00	8,120	154,280	1,179,524	Feb 04 07:48 PM
ROBINS CHAD M	CEO and Chairman	Feb 02 '26	Sale	18.44	124,998	2,304,963	2,459,245	Feb 04 07:37 PM
Harlan Robins	Officer	Feb 03 '26	Proposed Sale	18.50	8,120	150,220		Feb 03 05:09 PM
Harlan Robins	Officer	Feb 02 '26	Proposed Sale	18.39	34,668	637,545		Feb 02 05:26 PM
Chad Robins	Officer	Feb 02 '26	Proposed Sale	18.39	124,998	2,298,713		Feb 02 05:24 PM
LO FRANCIS	Chief People Officer	Jan 12 '26	Option Exercise	7.71	79,590	614,022	395,568	Jan 14 07:42 PM
LO FRANCIS	Chief People Officer	Jan 12 '26	Sale	17.73	79,590	1,411,131	315,978	Jan 14 07:42 PM
PISKEL KYLE	Chief Financial Officer	Jan 12 '26	Option Exercise	12.14	4,290	52,081	220,927	Jan 14 07:17 PM
PISKEL KYLE	Chief Financial Officer	Jan 12 '26	Sale	18.00	4,290	77,220	216,637	Jan 14 07:17 PM
FRANCIS LO	Officer	Jan 12 '26	Proposed Sale	15.76	64,293	1,013,258		Jan 12 04:27 PM
KYLE PISKEL	Officer	Jan 12 '26	Proposed Sale	15.76	11,081	174,637		Jan 12 04:26 PM
ROBINS HARLAN S	Chief Scientific Officer	Jan 06 '26	Sale	16.44	10,000	164,400	1,222,312	Jan 08 08:17 PM
ROBINS CHAD M	CEO and Chairman	Jan 05 '26	Sale	15.59	124,998	1,948,719	2,584,243	Jan 07 08:30 PM
LO FRANCIS	Chief People Officer	Jan 02 '26	Option Exercise	3.99	3,125	12,469	319,103	Jan 06 07:52 PM
LO FRANCIS	Chief People Officer	Jan 02 '26	Sale	16.08	3,125	50,250	315,978	Jan 06 07:52 PM
Harlan Robins	Officer	Jan 06 '26	Proposed Sale	16.11	10,000	161,100		Jan 06 04:57 PM
Chad Robins	Officer	Jan 05 '26	Proposed Sale	16.17	124,998	2,021,218		Jan 05 06:22 PM
LO FRANCIS	Chief People Officer	Dec 22 '25	Option Exercise	7.18	4,394	31,530	320,372	Dec 29 06:27 PM
LO FRANCIS	Chief People Officer	Dec 22 '25	Sale	17.50	4,394	76,895	315,978	Dec 29 06:27 PM
LO FRANCIS	Chief People Officer	Dec 15 '25	Option Exercise	6.37	97,022	617,766	429,868	Dec 17 07:06 PM
LO FRANCIS	Chief People Officer	Dec 15 '25	Sale	15.57	113,890	1,773,267	315,978	Dec 17 07:06 PM
FRANCIS LO	Officer	Dec 15 '25	Proposed Sale	15.44	136,706	2,110,741		Dec 15 04:24 PM
HERSHBERG ROBERT	Director	Dec 10 '25	Sale	16.00	22,968	367,488	46,722	Dec 12 07:11 PM
ROBERT M HERSHBERG	Director	Dec 10 '25	Proposed Sale	16.00	22,968	367,488		Dec 10 04:03 PM
BENZENO SHARON	Chief Commercial Ofc Imm Med	Dec 04 '25	Option Exercise	8.24	12,604	103,835	309,395	Dec 08 08:00 PM
BENZENO SHARON	Chief Commercial Ofc Imm Med	Dec 04 '25	Sale	16.85	12,604	212,377	296,791	Dec 08 08:00 PM
ROBINS HARLAN S	Chief Scientific Officer	Dec 03 '25	Sale	18.61	27,212	506,415	1,242,312	Dec 05 06:30 PM
ROBINS HARLAN S	Chief Scientific Officer	Dec 04 '25	Sale	16.61	10,000	166,100	1,232,312	Dec 05 06:30 PM
Harlan Robins	Officer	Dec 04 '25	Proposed Sale	17.46	10,000	174,600		Dec 04 05:15 PM
SHARON BENZENO	Officer	Dec 04 '25	Proposed Sale	17.13	12,604	215,907		Dec 04 04:38 PM
Harlan Robins	Officer	Dec 03 '25	Proposed Sale	17.13	27,212	466,142		Dec 03 05:58 PM
PISKEL KYLE	Chief Financial Officer	Nov 28 '25	Option Exercise	11.38	110,114	1,253,541	379,457	Dec 02 06:45 PM
PISKEL KYLE	Chief Financial Officer	Nov 28 '25	Sale	19.50	162,820	3,174,990	216,637	Dec 02 06:45 PM
ROBINS CHAD M	CEO and Chairman	Dec 01 '25	Sale	18.94	124,998	2,367,462	2,709,241	Dec 01 07:27 PM
ROBINS CHAD M	CEO and Chairman	Nov 26 '25	Sale	19.68	35,736	703,284	2,834,239	Dec 01 07:27 PM
Chad Robins	Officer	Dec 01 '25	Proposed Sale	18.84	124,998	2,354,962		Dec 01 06:03 PM
KYLE PISKEL	Officer	Nov 28 '25	Proposed Sale	19.72	162,820	3,210,810		Nov 28 01:18 PM
Chad Robins	Officer	Nov 26 '25	Proposed Sale	19.72	35,736	704,714		Nov 26 05:30 PM
BENZENO SHARON	Chief Commercial Ofc Imm Med	Nov 21 '25	Option Exercise	8.11	308,477	2,501,922	605,268	Nov 24 09:39 PM
BENZENO SHARON	Chief Commercial Ofc Imm Med	Nov 20 '25	Option Exercise	9.72	201,993	1,962,637	594,716	Nov 24 09:39 PM
BENZENO SHARON	Chief Commercial Ofc Imm Med	Nov 21 '25	Sale	16.91	308,477	5,216,346	296,791	Nov 24 09:39 PM
BENZENO SHARON	Chief Commercial Ofc Imm Med	Nov 20 '25	Sale	16.54	297,925	4,927,680	296,791	Nov 24 09:39 PM
SHARON BENZENO	Officer	Nov 21 '25	Proposed Sale	16.32	308,837	5,040,220		Nov 21 04:45 PM
SHARON BENZENO	Officer	Nov 20 '25	Proposed Sale	15.15	201,993	3,060,194		Nov 20 04:25 PM
SHARON BENZENO	Officer	Nov 19 '25	Proposed Sale	13.75	95,932	1,319,065		Nov 19 04:22 PM
PISKEL KYLE	Chief Financial Officer	Nov 17 '25	Sale	14.05	238	3,344	269,343	Nov 18 07:14 PM
ROBINS HARLAN S	Chief Scientific Officer	Nov 10 '25	Sale	14.82	10,000	148,200	1,269,524	Nov 12 07:30 PM
ROBINS CHAD M	CEO and Chairman	Nov 10 '25	Sale	14.73	86,161	1,269,152	2,873,088	Nov 12 07:19 PM
ROBINS CHAD M	CEO and Chairman	Nov 12 '25	Sale	15.00	1,867	28,005	2,869,975	Nov 12 07:19 PM
ROBINS CHAD M	CEO and Chairman	Nov 11 '25	Sale	14.57	1,237	18,023	2,871,851	Nov 12 07:19 PM
Chad Robins	Officer	Nov 12 '25	Proposed Sale	14.50	1,876	27,202		Nov 12 04:58 PM
Chad Robins	Officer	Nov 11 '25	Proposed Sale	14.53	1,237	17,974		Nov 12 08:09 AM
Chad Robins	Officer	Nov 10 '25	Proposed Sale	14.71	86,161	1,267,428		Nov 10 06:48 PM
Harlan Robins	Officer	Nov 10 '25	Proposed Sale	14.71	10,000	147,100		Nov 10 06:48 PM
PISKEL KYLE	Chief Financial Officer	May 16 '25	Sale	8.89	1,929	17,149	277,396	May 19 07:59 PM
ROBINS HARLAN S	Chief Scientific Officer	May 01 '25	Option Exercise	6.32	68,412	432,364	1,347,936	May 05 05:27 PM
ROBINS HARLAN S	Chief Scientific Officer	May 01 '25	Sale	7.35	68,412	502,828	1,279,524	May 05 05:27 PM
Harlan Robins	Officer	May 01 '25	Proposed Sale	7.36	68,412	503,512		May 01 05:38 PM
ROBINS HARLAN S	Chief Scientific Officer	Mar 24 '25	Option Exercise	6.32	1,698	10,731	1,281,222	Mar 26 06:48 PM
ROBINS HARLAN S	Chief Scientific Officer	Mar 24 '25	Sale	9.00	1,698	15,282	1,279,524	Mar 26 06:48 PM
Harlan Robins	Officer	Mar 24 '25	Proposed Sale	8.66	1,698	14,705		Mar 24 05:45 PM
PISKEL KYLE	Chief Financial Officer	Mar 14 '25	Option Exercise	6.32	2,500	15,800	271,510	Mar 17 07:34 PM
GRIFFIN MICHELLE RENEE	Director	Mar 13 '25	Sale	7.19	36,291	260,932	15,394	Mar 17 07:33 PM
GRIFFIN MICHELLE RENEE	Director	Mar 13 '25	Proposed Sale	7.19	36,291	260,861		Mar 13 05:28 PM
HERSHBERG ROBERT	Director	Mar 12 '25	Sale	7.59	53,000	402,270	69,690	Mar 12 07:48 PM
NEUPERT PETER M	Director	Mar 10 '25	Option Exercise	4.07	50,000	203,500	234,690	Mar 12 07:47 PM
NEUPERT PETER M	Director	Mar 10 '25	Sale	7.05	10,000	70,500	224,690	Mar 12 07:47 PM
HERSHBERG ROBERT	Director	Mar 12 '25	Proposed Sale	7.59	53,000	402,270		Mar 12 05:30 PM
NEUPERT PETER M	Director	Mar 10 '25	Proposed Sale	7.05	10,000	70,450		Mar 10 02:48 PM
LO FRANCIS	Chief People Officer	Mar 05 '25	Sale	6.99	20,875	145,845	332,846	Mar 06 07:22 PM
BOBULSKY SUSAN	Chief Commercial Officer, MRD	Mar 05 '25	Sale	6.98	26,023	181,641	347,238	Mar 06 07:22 PM
BENZENO SHARON	Chief Commercial Ofc Imm Med	Mar 05 '25	Sale	6.98	44,665	311,792	392,723	Mar 06 07:21 PM
PISKEL KYLE	Chief Financial Officer	Mar 05 '25	Sale	6.98	10,320	72,072	269,010	Mar 06 07:20 PM
RUBINSTEIN JULIE	President and COO	Mar 05 '25	Sale	6.98	59,505	415,540	588,249	Mar 06 07:19 PM
ROBINS HARLAN S	Chief Scientific Officer	Mar 05 '25	Sale	6.99	96,656	675,219	1,279,524	Mar 06 07:18 PM
ROBINS CHAD M	CEO and Chairman	Mar 05 '25	Sale	6.98	117,351	819,471	2,814,350	Mar 06 07:17 PM
ROBINS CHAD M	CEO and Chairman	Mar 06 '25	Sale	7.64	102,218	780,946	2,959,249	Mar 06 07:17 PM
GRIFFIN MICHELLE RENEE	Director	Mar 06 '25	Sale	7.94	15,664	124,372	51,685	Mar 06 07:14 PM
MICHELLE GRIFFIN	Director	Mar 06 '25	Proposed Sale	7.94	15,664	124,440		Mar 06 04:10 PM
ROBINS CHAD M	CEO and Chairman	Feb 19 '25	Option Exercise	6.32	186,080	1,176,026	2,762,781	Feb 21 07:28 PM
ROBINS CHAD M	CEO and Chairman	Feb 20 '25	Option Exercise	6.32	99,107	626,356	2,675,808	Feb 21 07:28 PM
ROBINS CHAD M	CEO and Chairman	Feb 19 '25	Sale	8.46	186,080	1,574,237	2,576,701	Feb 21 07:28 PM
ROBINS CHAD M	CEO and Chairman	Feb 20 '25	Sale	8.44	99,107	836,463	2,576,701	Feb 21 07:28 PM
Chad Robins	Officer	Feb 20 '25	Proposed Sale	8.37	99,107	829,526		Feb 20 04:02 PM
Chad Robins	Officer	Feb 19 '25	Proposed Sale	8.37	186,080	1,557,490		Feb 19 04:51 PM
ROBINS CHAD M	CEO and Chairman	Feb 18 '25	Option Exercise	6.32	211,160	1,334,531	2,787,861	Feb 18 08:21 PM
ROBINS CHAD M	CEO and Chairman	Feb 14 '25	Option Exercise	6.32	158,921	1,004,381	2,735,622	Feb 18 08:21 PM
ROBINS CHAD M	CEO and Chairman	Feb 13 '25	Option Exercise	6.32	100,287	633,814	2,676,988	Feb 18 08:21 PM
ROBINS CHAD M	CEO and Chairman	Feb 18 '25	Sale	8.50	211,160	1,794,860	2,576,701	Feb 18 08:21 PM
ROBINS CHAD M	CEO and Chairman	Feb 14 '25	Sale	8.46	158,921	1,344,472	2,576,701	Feb 18 08:21 PM
ROBINS CHAD M	CEO and Chairman	Feb 13 '25	Sale	8.44	100,287	846,422	2,576,701	Feb 18 08:21 PM
Chad Robins	Officer	Feb 18 '25	Proposed Sale	8.27	211,160	1,746,293		Feb 18 05:35 PM
Chad Robins	Officer	Feb 14 '25	Proposed Sale	8.33	158,921	1,323,812		Feb 14 04:11 PM
Chad Robins	Officer	Feb 13 '25	Proposed Sale	8.52	100,287	854,445		Feb 13 05:11 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ADPT

Adaptive Biotechnologies Corp

Upgrade your FINVIZ experience